导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.12% | 3898/4773 |
| 近一周 | -2.52% | 3988/5465 |
| 近一月 | -2.71% | 1836/5421 |
| 近一季 | -2.34% | 1356/5231 |
| 近半年 | -4.21% | 2754/4920 |
| 近一年 | -15.26% | 3718/4394 |
| 近两年 | 31.09% | 2238/2954 |
| 近三年 | 12.35% | 1699/2253 |
| 成立以来 | 21.87% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.32% 4639/4961 |
8.72% 2553/5312 |
- - |
- - |
| 2025 | 4.19% 3061/4813 |
-6.54% 3364/3635 |
4.29% 803/4076 |
11.02% 3209/4524 |
-3.71% 3321/4813 |
| 2024 | 29.33% 132/3463 |
-4.61% 1718/2808 |
-7.70% 2114/3014 |
43.14% 19/3129 |
2.62% 919/3463 |
| 2023 | 4.11% 244/2656 |
4.05% 1061/2280 |
-2.75% 651/2385 |
7.45% 39/2515 |
-4.25% 935/2655 |
| 2022 | -24.16% 1196/2207 |
-17.55% 1215/1919 |
2.07% 1365/2016 |
-14.96% 1177/2113 |
5.97% 404/2208 |
| 2021 | -2.44% 855/1822 |
-14.11% 1167/1255 |
6.80% 717/1330 |
4.31% 366/1466 |
1.95% 740/1822 |
| 2020 | 14.72% 791/1250 |
-11.08% 816/1028 |
6.98% 850/1067 |
21.86% 38/1164 |
-1.03% 1090/1184 |
| 2019 | 50.29% 100/1092 |
47.37% 12/754 |
-5.22% 457/804 |
-2.85% 716/850 |
10.75% 100/918 |
| 2018 | -22.96% 265/834 |
- - |
- - |
- - |
-1.41% 14/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国泰中证申万证券行业指数(LOF)A VS. 长安沪深300非周期A(740101) |